Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573435 | 0.94 | JAK3 (0.31) | JAK3 | |
| SCHEMBL25854705 | 0.78 | EPHX2 (0.33) | TRPA1JAK3EPHX1SMN1; SMN2MAPT | |
| SCHEMBL18920053 | 0.76 | BDKRB1 (0.37) | EPHX1MAPT | |
| SCHEMBL20899681 | 0.75 | — | — | |
| SCHEMBL28208402 | 0.75 | — | — | |
| SCHEMBL5751425 | 0.74 | PGR (0.39) | TRPA1JAK3SMN1; SMN2MAPT | |
| SCHEMBL12493161 | 0.74 | PGR (0.39) | TRPA1JAK3SMN1; SMN2MAPT | |
| SCHEMBL764581 | 0.72 | BTK (0.44) | EPHX1 | |
| SCHEMBL3582508 | 0.72 | TRPA1 (0.32) | TRPA1MAPT | |
| SCHEMBL761810 | 0.71 | EPHX1 (0.54) | EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2387315-B1 | IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-07-15 | — | — | EP | disclosed |
| EP-2855458-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Reset Therapeutics, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| WO-2013170186-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | CRY1, CRY2, CRYAB | TRPA1 1467/4885JAK3 2060/4885CETP 1274/4885 |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | TRPA1 1451/4885JAK3 1943/4885CETP 1324/4885 |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | CRY1, CRY2, CRYAB | TRPA1 1451/4885JAK3 1943/4885CETP 1324/4885 |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | TRPA1 1451/4885JAK3 1943/4885CETP 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.